Bo Ci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bo Ci has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- David E. Gerber
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX
2 shared publications Andreas Heilmann
Foundation Medicine, Cambridge, TX
1 shared publicationBarbara Burtness
Yale University-Yale Cancer Center, New Haven, CT
1 shared publicationDavid G McFadden
UT Southwestern, Dallas, TX
1 shared publication- Guanghua Xiao
Quantitative Biomedical Research Center, Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication - Jeffrey S. Ross
Foundation Medicine Inc, Cambridge, Massachusetts
1 shared publication
Latest Publications
- Open Access
Development and Validation of a Nomogram Prognostic Model for Small-Cell Lung Cancer Patients
Background: Small-cell lung cancer (SCLC) accounts for almost 15% of lung cancer cases in the United States. Nomogram prognostic models could greatly facilitate risk stratification and treatment planning, as well as more refined enrollment criteria for clinical trials. We developed and validated a new nomogram prognostic model for SCLC patients using a large SCLC patient cohort from the National Cancer Database (NCDB). Methods: Clinical data of 24,680 SCLC patients diagnosed from 2004 to 2011 were used to develop the nomogram prognostic model. The model was then validated using an independent cohort of 9,700 SCLC patients diagnosed from 2012 to 2013. The prognostic performance was evaluated using p value, concordance index and integrated Area Under the (time dependent Receiver Operating Characteristic) Curve. Results: The following variables were contained in the final prognostic model: age, gender, race, ethnicity, Charlson/Deyo Score, TNM Stage (assigned according to the AJCC 8 th edition), treatment type (combination of surgery, radiation therapy and chemotherapy), and laterality. The model was validated in an independent testing group with a concordance index of 0.722 ± 0.004 and an integrated AUC of 0.79. The nomogram model has a significantly higher prognostic accuracy than previously developed models, including the AJCC 8 th edition TNM-staging system. We implemented the proposed nomogram and two previously published nomograms in an online webserver. Conclusions: We developed a nomogram prognostic model for SCLC patients, and validated the model using an independent patient cohort. The nomogram performs better than earlier models, including AJCC staging.
Open AccessDevelopment and Validation of a Nomogram Prognostic Model for Small-Cell Lung Cancer Patients
Background: Small-cell lung cancer (SCLC) accounts for almost 15% of lung cancer cases in the United States. Nomogram prognostic models could greatly facilitate risk stratification and treatment planning, as well as more refined enrollment criteria for clinical trials. We developed and validated a new nomogram prognostic model for SCLC patients using a large SCLC patient cohort from the National Cancer Database (NCDB). Methods: Clinical data of 24,680 SCLC patients diagnosed from 2004 to 2011 were used to develop the nomogram prognostic model. The model was then validated using an independent cohort of 9,700 SCLC patients diagnosed from 2012 to 2013. The prognostic performance was evaluated using p value, concordance index and integrated Area Under the (time dependent Receiver Operating Characteristic) Curve. Results: The following variables were contained in the final prognostic model: age, gender, race, ethnicity, Charlson/Deyo Score, TNM Stage (assigned according to the AJCC 8 th edition), treatment type (combination of surgery, radiation therapy and chemotherapy), and laterality. The model was validated in an independent testing group with a concordance index of 0.722 ± 0.004 and an integrated AUC of 0.79. The nomogram model has a significantly higher prognostic accuracy than previously developed models, including the AJCC 8 th edition TNM-staging system. We implemented the proposed nomogram and two previously published nomograms in an online webserver. Conclusions: We developed a nomogram prognostic model for SCLC patients, and validated the model using an independent patient cohort. The nomogram performs better than earlier models, including AJCC staging.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6014
Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).
6014 Background: ATC is the most aggressive type of thyroid cancer with a median survival of 5 months from diagnosis. ATC patients with genomic alterations (GA) in TSC2, ALK, BRAF show occasional, limited benefit with targeted therapies. Methods: 90 ATC were studied by CGP to define the frequency of GA and opportunities for targeted therapy approaches in this devastating disease. DNA was extracted from 40 microns of FFPE sections, and CGP was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 579X for up to 315 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. GA included base substitutions, indels, amplifications, copy number alterations and fusions/rearrangements. R software used for all statistical analyses. Fisher’s exact test used for mutation frequency comparisons among age groups. Results: Median patient age was 65 (range 33-86), 50 patients were male. There was a mean of 4.2 Known Likely Variant (KLV) genomic alterations per case, range 1-11. Adding Variants of Undetermined Significance (VUS) mean was 12.9, range 5-27. The most common KLV-GA were p53 (66%), BRAF (34%), TERT (32%), CDKN2A (32%), NRAS (26%), CDKN2B (20%), NF2 (14.4%), PTEN (13.3%), PIK3CA (12.2%). There were 2 EGFR; 5 JAK2 and 29 GAin the promoter region of TERT. BRAF V600E and NRAS/HRAS alteration were entirely mutually exclusive, and one case demonstrated both BRAF V600E and KRAS. Co-occuring mutations were CDKN2A with p53 (p=0.04). Some GA were more frequent in patients greater than ≥70 yrs of age such as BRAF, CDKN2A, PIK3CA, JAK2; while others were more common in ≤50 yrs patients like PTEN, NRAS. VUS of possible interest were MLL2 (n=15), ARID1A (11), TSC2 (5), ALK(2). Conclusions: A number of identified alterations in ATC patients may be amenable to molecularly targeted therapies, guiding future clinical trial development. Further assessment will be performed to the relationship of GA in ATC with patient demographics and disease evolution from differentiated thyroid carcinoma.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6014
Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).
6014 Background: ATC is the most aggressive type of thyroid cancer with a median survival of 5 months from diagnosis. ATC patients with genomic alterations (GA) in TSC2, ALK, BRAF show occasional, limited benefit with targeted therapies. Methods: 90 ATC were studied by CGP to define the frequency of GA and opportunities for targeted therapy approaches in this devastating disease. DNA was extracted from 40 microns of FFPE sections, and CGP was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 579X for up to 315 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. GA included base substitutions, indels, amplifications, copy number alterations and fusions/rearrangements. R software used for all statistical analyses. Fisher’s exact test used for mutation frequency comparisons among age groups. Results: Median patient age was 65 (range 33-86), 50 patients were male. There was a mean of 4.2 Known Likely Variant (KLV) genomic alterations per case, range 1-11. Adding Variants of Undetermined Significance (VUS) mean was 12.9, range 5-27. The most common KLV-GA were p53 (66%), BRAF (34%), TERT (32%), CDKN2A (32%), NRAS (26%), CDKN2B (20%), NF2 (14.4%), PTEN (13.3%), PIK3CA (12.2%). There were 2 EGFR; 5 JAK2 and 29 GAin the promoter region of TERT. BRAF V600E and NRAS/HRAS alteration were entirely mutually exclusive, and one case demonstrated both BRAF V600E and KRAS. Co-occuring mutations were CDKN2A with p53 (p=0.04). Some GA were more frequent in patients greater than ≥70 yrs of age such as BRAF, CDKN2A, PIK3CA, JAK2; while others were more common in ≤50 yrs patients like PTEN, NRAS. VUS of possible interest were MLL2 (n=15), ARID1A (11), TSC2 (5), ALK(2). Conclusions: A number of identified alterations in ATC patients may be amenable to molecularly targeted therapies, guiding future clinical trial development. Further assessment will be performed to the relationship of GA in ATC with patient demographics and disease evolution from differentiated thyroid carcinoma.